

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 24275

**Title:** von Willebrand factor antigen as a therapeutic target of portal hypertension in cirrhosis

**Reviewer's code:** 00071220

**Reviewer's country:** Japan

**Science editor:** Ze-Mao Gong

**Date sent for review:** 2016-01-18 10:35

**Date reviewed:** 2016-01-18 13:12

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

## COMMENTS TO AUTHORS

I had the opportunity to review a paper "von Willebrand factor antigen as a therapeutic target of portal hypertension in cirrhosis", and I found very interesting. There is no problem to publish the manuscript.

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 24275

**Title:** von Willebrand factor antigen as a therapeutic target of portal hypertension in cirrhosis

**Reviewer's code:** 03024263

**Reviewer's country:** Russia

**Science editor:** Ze-Mao Gong

**Date sent for review:** 2016-01-18 10:35

**Date reviewed:** 2016-01-19 14:45

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

## COMMENTS TO AUTHORS

Indeed, sinusoidal endothelial dysfunction is a key mediator of increase intrahepatic vascular resistance, that plays an important role in the pathogenesis of portal hypertension in liver cirrhosis. von Willebrand factor antigen may be a factor which initially involved to intrahepatic endothelial dysfunction and subsequently predisposes to portal microthrombosis. Thus, we can agree with the authors, who suggest that increased thrombotic potential within the liver sinusoids due to high concentrations of von Willebrand factor antigen macromolecules could represent an additional therapeutic target of portal hypertension in patients with liver cirrhosis.

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 24275

**Title:** von Willebrand factor antigen as a therapeutic target of portal hypertension in cirrhosis

**Reviewer's code:** 01557045

**Reviewer's country:** Mexico

**Science editor:** Ze-Mao Gong

**Date sent for review:** 2016-01-18 10:35

**Date reviewed:** 2016-01-20 01:13

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input checked="" type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

## COMMENTS TO AUTHORS

Nice complement and addition to the paper of Garbuzenko et al.

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 24275

**Title:** von Willebrand factor antigen as a therapeutic target of portal hypertension in cirrhosis

**Reviewer's code:** 00225277

**Reviewer's country:** Spain

**Science editor:** Ze-Mao Gong

**Date sent for review:** 2016-01-18 10:35

**Date reviewed:** 2016-01-24 04:09

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input checked="" type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

## COMMENTS TO AUTHORS

In the present letter regarding the study on Portal Hypertension by Garbuzenko, Kalambokis states that increased thrombotic activity plays an important role in the development of portal hypertension (PH) and also with major associated PH-related events. This aspect should be considered in the treatment of these patients because the use of anti-inflammatory and antithrombotic agents could be another associated treatment for the prevention of intrahepatic platelet-induced microthrombi, which may modify the evolution of PH. The letter provides complementary data to the Garbuzenko paper and its publication introduces more information to the readers. Moreover, up to date bibliography cited by Kalambokis enhances the interest of this aspect in the pathogenesis and treatment of PH. The letter should be admitted for publication.